These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3257902)

  • 1. The immunological mouse mutants nude (nu) and rhino (hrrh) generate cytotoxic effector cells following adoptive immunotherapy but fail to reject a transplanted tumor.
    Evans R; Duffy TM; Shultz LD
    Cancer Immunol Immunother; 1988; 26(1):35-42. PubMed ID: 3257902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy is suppressed in C57BL/6J and B6.C-H-2bm12 mice following recognition of congenic class II MHC antigen determinants.
    Evans R; Duffy TM
    Int J Cancer; 1989 Nov; 44(5):854-8. PubMed ID: 2479606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with a tumor-infiltrating lymphocyte clone, soluble antigen, and cyclophosphamide.
    Komichi H; Smith S; Kahan BD
    Arch Surg; 1992 Dec; 127(12):1417-23. PubMed ID: 1365687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two distinct populations of primary cytotoxic cells infiltrating into allografted tumor rejection sites: infiltration of macrophages cytotoxic against allografted tumor precedes that of multiple sets of cytotoxic T lymphocytes with distinct specificity to alloantigens.
    Yoshida R; Matsuura A; Einaga K; Ushio Y; Yamamoto N; Yoneda Y
    Microbiol Immunol; 1997; 41(2):149-59. PubMed ID: 9087957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
    Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E
    J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological status of nude mice engrafted with allogeneic or syngeneic thymuses.
    Furukawa F; Ikehara S; Good RA; Nakamura T; Inoue S; Tanaka H; Imamura S; Hamashima Y
    Thymus; 1988; 12(1):11-26. PubMed ID: 2977452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor-sensitized T lymphocytes: potential mechanisms of action.
    Evans R
    Int J Cancer; 1984 Mar; 33(3):381-8. PubMed ID: 6607893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active specific chemoimmunotherapy of lymph-node metastasis from a poorly immunogenic murine fibrosarcoma.
    Naito K; Oka T; Nomi S; Yamagishi H; Kahan BD
    Jpn J Cancer Res; 1989 Nov; 80(11):1119-26. PubMed ID: 2514172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.
    Greenberg PD; Kern DE; Cheever MA
    J Exp Med; 1985 May; 161(5):1122-34. PubMed ID: 3921652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma.
    Maglioco A; Machuca D; Mundiñano J; Cabrera G; Camicia G; Bruzzo J; Camerano G; Costa H; Ruggiero RA; Dran GI
    Cancer Immunol Immunother; 2011 Mar; 60(3):389-99. PubMed ID: 21153814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
    Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
    Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunity in immune-deficient scid/scid mice. I. Differential requirements of naive and primed lymphocytes for CD4+ T cells during rejection of minor histocompatibility antigen-disparate skin grafts.
    Roopenian DC; Anderson PS
    Transplantation; 1988 Dec; 46(6):899-904. PubMed ID: 2905088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inability of adoptive immunotherapy to eradicate tumor cells in radiation-induced chimeric mice: the possible down-regulation of intratumor immune amplification.
    Evans R; Duffy TM
    Int J Cancer; 1987 Feb; 39(2):226-31. PubMed ID: 2948923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of class II-MHC antigens by tumor-associated and peritoneal macrophages: systemic induction during tumor growth and tumor rejection.
    Evans R; Blake SS; Saffer JD
    J Leukoc Biol; 1986 Nov; 40(5):499-509. PubMed ID: 3464672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
    North RJ
    J Exp Med; 1982 Apr; 155(4):1063-74. PubMed ID: 6460831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector mechanisms of syngeneic anti-tumour responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukaemia RL male 1 in the nude mouse system.
    Keyaki A; Kuribayashi K; Sakaguchi S; Masuda T; Yamashita J; Handa H; Nakayama E
    Immunology; 1985 Sep; 56(1):141-51. PubMed ID: 3876272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
    Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.